Pharmacological prophylaxis of choice in venous thromboembolic disease in major orthopedic surgery: aspirin vs LMWH and other anticoagulants
DOI:
https://doi.org/10.56294/ri202619Keywords:
Orthopedic surgery, venous thromboembolism, prophylaxis, Arthroplasty Replacement Hip/Knee, Aspirin, Heparin Low-Molecular-WeighAbstract
Introduction: Venous thromboembolic disease, deep vein thrombosis and pulmonary embolism are important causes of long-term morbidity and mortality, and are preventable. The risk of VTE is established in patients who will undergo major orthopedic surgery, given by factors such as the duration of surgery and reduced perioperative mobility.
Studies show that without pharmacological thrombo prophylaxis, VTE rates are significant. For this reason, it is essential to establish an effective thrombo prophylaxis protocol to prevent VTE without significantly increasing the risk of bleeding. There is no evidence with strong results regarding the drug of choice for thrombo prophylaxis, but currently meta-analyses and systematic reviews establish aspirin as an effective, accessible and low-cost option, with low risk of postoperative bleeding in low-risk patients.
Aspirin is an easy-to-administer drug, does not require blood monitoring and is well tolerated, with an excellent safety profile. However, there are some theories that newer oral agents may have higher risks of bleeding, such as major hemorrhages and complications from postsurgical wounds. Therefore, there is still considerable debate about which agents should be preferred in terms of effectiveness and lower risk of bleeding.
Objectives: To establish the drug of choice for thromboprophylaxis in VTE in patients undergoing major orthopedic surgery.
Materials and methods: A bibliographic search and analysis was carried out, only 15 articles were suitable for the research, articles from international databases such as PubMed, Scopus and Cinahl were used.
Results: There were no significant differences in the risk of VTE (OR = 0.93; 95% CI: 0.69-1.26; p = 0.64), DVT (OR = 0.72; 95% CI: 0.43-1.20; p = 0.21) or PTE (OR = 1.13; 95% CI: 0.86-1.49; p = 0.38) between the groups that received LMWH prophylaxis and those that received aspirin. Nor were significant differences found in mortality (p = 0.30), bleeding (p = 0.22), or surgical wound complications (p = 0.85) between the two groups.
Conclusion: aspirin is at least as safe and effective a drug for thromboprophylaxis as OACs and LMWH.
References
1. Vázquez FJ, Grande Ratti MF. Incidencia de la enfermedad tromboembólica venosa adquirida en la internacionalización [Internet]. Org.ar; 2018 [citado 16 jul 2024]. Disponible en: https://www1.hospitalitaliano.org.ar/multimedia/archivos/noticias_attachs/47/documentos/76938_163-164%20HI4-10-Vazquez-A.pdf
2. Gutiérrez Guisado J. Profilaxis tromboembólica en cirugía ortopédica y traumatología. Rev Clin Esp [Internet]. 2020;220:25–32. Disponible en: http://dx.doi.org/10.1016/j.rce.2020.04.016
3. Gutiérrez M, Leache L, Saiz LC, Erviti J. Profilaxis antitrombótica en cirugía ortopédica y traumatología [Internet]. Navarra.es; 2021 [citado 16 jul 2024]. Disponible en: https://www.navarra.es/NR/rdonlyres/B392D594-8010-4121-8F7B-7BA4BE674260/474710/Profilaxisantitrombotica_def.pdf
4. Rodríguez FC. Módulo 5: Tromboprofilaxis en traumatología y cirugía deportiva [Internet]. Campus.sanofi; 2023. Disponible en: https://pro.campus.sanofi/es/osteoartritis/recursos/actualizacion-recomendaciones-tromboprofilaxis-traumatologia-cirugia-deportiva
5. Núñez JH, Moreira F, Escudero-Cisneros B, Martínez-Peña J, Bosch-García D, Anglès F, et al. Riesgo de tromboembolismo venoso entre aspirina y HBPM tras artroplastia total de cadera o rodilla: revisión sistemática y metaanálisis. Rev Esp Cir Ortop Traumatol [Internet]. 2024;68(4):409–21. Disponible en: http://dx.doi.org/10.1016/j.recot.2023.07.003
6. Castel Oñate A. Cambio de paradigma en la tromboprofilaxis en COT [Internet]. Secot.es; 2023 [citado 16 jul 2024]. Disponible en: https://www.secot.es/media/docs/guiatromboprofilaxis/Gu%C3%ADa%20Tromboprofilaxis.pdf
7. Migliorini F, Maffulli N, Velaj E, Bell A, Kämmer D, Hildebrand F, et al. Antithrombotic prophylaxis following total hip arthroplasty: Bayesian network meta-analysis. J Orthop Traumatol [Internet]. 2024;25(1). Disponible en: http://dx.doi.org/10.1186/s10195-023-00742-2
8. Sidhu VS, Kelly TL, Pratt N, Graves SE, Buchbinder R, et al. Effect of aspirin vs enoxaparin in arthroplasty: CRISTAL trial. JAMA [Internet]. 2022;328(8):719. Disponible en: http://dx.doi.org/10.1001/jama.2022.13416
9. Marrannes S, Victor K, Arnout N, De Backer T, Victor J, Tampere T. VTE prevention with aspirin after knee surgery: review. EFORT Open Rev [Internet]. 2021;6(10):892–904. Disponible en: http://dx.doi.org/10.1302/2058-5241.6.200120
10. Farey JE, An VVG, Sidhu V, Karunaratne S, Harris IA. Aspirin vs enoxaparin for VTE prophylaxis: meta-analysis. Orthop Traumatol Surg Res [Internet]. 2021;107(1):102606. Disponible en: http://dx.doi.org/10.1016/j.otsr.2020.04.002
11. Ma JK, Chen YQ, Zhang LY. DOACs vs aspirin for thromboembolism after arthroplasty: review [Internet]. Europeanreview.org [citado 16 jul 2024]. Disponible en: https://www.europeanreview.org/wp/wp-content/uploads/6245-6259.pdf
12. Singh G, Prentice HA, Winston BA, Kroger EW. Aspirin vs anticoagulants: cohort of 107,000 arthroplasty patients. J Arthroplasty [Internet]. 2023;38(8):1602-1612.e1. Disponible en: http://dx.doi.org/10.1016/j.arth.2023.02.021
13. Reddy GB, Ovadia JE, Yakkanti RR, et al. Morbidity with PE after joint arthroplasty: matched analysis. J Arthroplasty [Internet]. 2022;37(5):948–52. Disponible en: http://dx.doi.org/10.1016/j.arth.2022.01.086
14. Diep R, Garcia D. Does aspirin prevent venous thromboembolism? Hematology Am Soc Hematol Educ Program [Internet]. 2020;2020(1):634–41. Disponible en: http://dx.doi.org/10.1182/hematology.2020000150
15. Pulmonary Embolism Prevention (PEP) trial. Low-dose aspirin for PE and DVT. Lancet. 2000;355(9212):1295–302.
16. Falck-Ytter Y, Francis CW, et al. Antithrombotic guidelines, 9th ed. Chest [Internet]. 2012;141(2 Suppl):e278S-e325S. Disponible en: http://dx.doi.org/10.1378/chest.11-2404
17. Anderson DR, Morgano GP, et al. ASH 2019 guidelines on VTE prevention. Blood Adv [Internet]. 2019;3(23):3898–944. Disponible en: http://dx.doi.org/10.1182/bloodadvances.2019000975
18. Gee E. VTE NICE guideline implementation: UK response. Br J Haematol [Internet]. 2019;186(5):792–3. Disponible en: http://dx.doi.org/10.1111/bjh.16010
19. CRISTAL Study Group. Aspirin vs enoxaparin: CRISTAL trial. JAMA [Internet]. 2022 [citado 12 oct 2024];328(8):719. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2795528
20. Parvizi J, DeMik DE, et al. LMWH vs aspirin for VTE: Is it better? J Arthroplasty [Internet]. 2023;38(1):1–2. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S0883540322008610
21. Chan NC, Bhandari M. Thromboprophylaxis after arthroplasty. JAMA [Internet]. 2022 [citado 12 oct 2024];328(8):712. Disponible en: https://jamanetwork.com/journals/jama/article-abstract/2795552
22. Richardson SS, et al. Pharmacologic prophylaxis after TKA. Knee [Internet]. 2019;26(2):451–8. Disponible en: https://linkinghub.elsevier.com/retrieve/pii/S096801601830704X
23. Hu B, et al. Rivaroxaban vs aspirin after arthroplasty or hip fracture: meta-analysis. J Orthop Surg Res [Internet]. 2021;16(1). Disponible en: http://dx.doi.org/10.1186/s13018-021-02274-z
24. Yhim HY, et al. VTE prophylaxis impact after arthroplasty in Korea. PLoS One [Internet]. 2017;12(5):e0178214. Disponible en: http://dx.doi.org/10.1371/journal.pone.0178214
25. Agaba P, et al. VTE complications after THA by drug. J Orthop [Internet]. 2017;14(4):537–43. Disponible en: http://dx.doi.org/10.1016/j.jor.2017.08.002
26. Pellegrini VD Jr, et al. Selection bias in aspirin research. J Bone Joint Surg Am [Internet]. 2020;102(7):631–3. Disponible en: http://dx.doi.org/10.2106/JBJS.19.01135
27. Lindquist DE, et al. Bleeding comparison in arthroplasty patients. Clin Appl Thromb Hemost [Internet]. 2018;24(8):1315–21. Disponible en: http://dx.doi.org/10.1177/1076029618772337
28. Shafiei SH, et al. Low vs high-dose aspirin after TJA: cohort study. Ann Med Surg (Lond) [Internet]. 2023;85(5):1461–7. Disponible en: http://dx.doi.org/10.1097/MS9.0000000000000366
29. Merkow DB, et al. Low-dose aspirin prevents VTE in TKA. J Orthop [Internet]. 2021;24:26–8. Disponible en: http://dx.doi.org/10.1016/j.jor.2021.02.005
30. Azboy I, et al. Low-dose aspirin for VTE in arthroplasty: review. J Arthroplasty [Internet]. 2019;35(3):886–92. Disponible en: http://dx.doi.org/10.1016/j.arth.2019.09.043
31. Mula V, et al. VTE after arthroplasty and hip fractures. BMC Musculoskelet Disord [Internet]. 2020;21(1):95. Disponible en: http://dx.doi.org/10.1186/s12891-020-3100-47
Published
Issue
Section
License
Copyright (c) 2026 Florencia Agustina Rosignoli , Fernando Lipovestky (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
